Please proceed with registration and ordering once you have received your approval letter and promotional code from GSC.
1: AkaRx Inc. Doptelet (avatrombopag) FDA Product Monograph. Reference ID: NDA210238, 07/2024.
2: Alkermes Inc. Aristada (aripiprazole lauroxil) FDA Product Monograph. Reference ID: NDA207533, 12/2023.
3: Amneal Pharmaceuticals NY LLC. Brexpiprazole FDA Product Monograph. Reference ID: ANDA213562, 03/2024.
4: Amstutz U, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase
Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216.
5: Avanir Pharmaceuticals, Inc. Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) FDA Product Monograph.
Reference ID: 4446950, 06/2019
6: Axsome Therapeutics, Inc. Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) FDA Product Monograph.
Reference ID: 5376564, 08/2022.
7: Bell GC, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of
ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218.
8: Biogen Inc. Aduhelm (aducanumab-avwa) FDA Product Monograph. Reference ID: 4807032, 06/2021.
9: Birdwell KA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus
Dosing. Clin Pharmacol Ther. 2015;98(1):19-24.
10: Bousman CA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6,
SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68.
11: Brown JT, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and
Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102.
12: Cadila Pharmaceuticals Limited. Fluoxetine FDA Product Monograph. Reference ID: ANDA206993, 07/2024.
13: Cooper-DeHoff RM, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and
CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021.
14: Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes
and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896.
15: Desta Z, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing
Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733.
16: Duarte JD, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C,
GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Clin Pharmacol Ther. 2024;116(4):939-947.
17: Dutch Pharmacogenetics Working Group (DPWG). Pharmacogenetic Recommendation Text. Jun 2023.
18: Eisai Inc. Leqembi (lecanemab-irmb) FDA Product Monograph. Reference ID: BLA761269, 01/2023.
19: Gammal RS, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir
Prescribing. Clin Pharmacol Ther. 2016;99(4):363-369.
20: Gammal RS, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the
Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5): 973-985.
21: Goetz MP, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Clin Pharmacol Ther. 2018;103(5):770-777.
22: Gonsalves SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile
Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes. Clin Pharmacol Ther. 2019;105(6):1338-
1344.
23: Harmony Biosciences, LLC. Wakix (pitolisant) FDA Product Monograph. Reference ID: NDA211150, 12/2022.
24: Hicks JK, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and
dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44.
25: Ipsen Biopharmaceuticals Inc. Onivyde (irinotecan) FDA Product Monograph. Reference ID: NDA207793, 02/2024.
26: Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided
Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404.
27: Karnes JH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and
Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309.
28: Lee CR, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel
Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967.
29: Lima JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor
Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423.
30: Lundbeck Pharmaceuticals LLC. Onfi (clobazam) FDA Product Monograph. Reference ID: NDA202067/ NDA203993, 03/2024.
31: Maillard M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and
NUDT15 Genotypes: 2025 Update. Clin Pharmacol Ther. 2026 Jan 31. doi: 10.1002/cpt.70209. Epub ahead of print.
32: Martin MA, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
Clin Pharmacol Ther. 2012;91(4):734-738.
33: McDermott JH, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on
MT-RNR1 Genotype. Clin Pharmacol Ther. 2022;111(2):366-372.
34: Moriyama B, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole
Therapy. Clin Pharmacol Ther. 2017;102(1):45-51.
35: Muir AJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG
interferon-α-based regimens. Clin Pharmacol Ther. 2014;95(2):141-146.
36: Novartis Pharmaceuticals Corporation. Mayzent FDA Drug Label. Reference ID: NDA209884, 08/2025.
37: Novartis Pharmaceuticals Corporation. Promacta (eltrombopag) FDA Product Monograph. Reference ID: 4599937, 04/2020.
38: Pfizer Laboratories Div Pfizer Inc. Cibinqo (abrocitinib) FDA Product Monograph. Reference ID: NDA213871, 12/2023.
39: Pharmacia & Upjohn Company LLC. Camptosar (irinotecan) FDA Product Monograph. Reference ID: NDA020571, 01/2022.
40: Phillips EJ, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine
and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018;103(4):574-581.
41: Robinson KM, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone
Therapy. Clin Pharmacol Ther. 2024;116(4):932-938.
42: Saito Y, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B)
genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36-37.
43: ScieGen Pharmaceuticals Inc. Aripiprazole FDA Product Monograph. Reference ID: ANDA207240, 08/2024.
44: Shionogi Inc. Mupleta (lusutrombopag) FDA Product Monograph. Reference ID: NDA210923, 10/2020.
45: Theken KN, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-
Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200.
46: US Food and Drug Administration. Table of Pharmacogenetic Associations: Section 1: Pharmacogenetic associations for which
the data support therapeutic management recommendations. Section 2: Pharmacogenetic associations for which the data
indicate a potential impact on safety or response. Section 3: Pharmacogenetic associations for which the data demonstrate a
potential impact on pharmacokinetic properties only. 2022. https://www.fda.gov/medical-devices/precision-medicine/tablepharmacogenetic-
associations
47: Whirl-Carrillo M, et al. Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2012;92(4):414-417.
PharmGKB Data Usage Policy: https://www.pharmgkb.org/page/dataUsagePolicy. The only changes from the original
PharmGKB content included in this report of record are related to formatting (adding a header).
48: Whirl-Carrillo M, Huddart R, et al. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized
Medicine. Clin Pharmacol Ther. 2021;110(3):563-572. PharmGKB Data Usage Policy:
https://www.pharmgkb.org/page/dataUsagePolicy. The only changes from the original PharmGKB content included in this
report of record are related to formatting (adding a header).
Legal Disclaimer: “The information provided on this website is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. GenXys does not endorse or promote any specific tests, physicians, products, procedures, opinions, or other information mentioned herein. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Use of this website is subject to the terms and conditions set forth in our Privacy Policy and Terms of Use. GenXys operates in accordance with the regulatory requirements of Canada but may not meet the regulations of other jurisdictions. By accessing and using this website, you agree to comply with all applicable local laws and regulations. If you do not agree, please do not use this site. Privacy and Data Disclaimer: “GenXys is committed to protecting the privacy and security of your personal information. We adhere to stringent data protection regulations in Canada and globally to ensure that your data is handled responsibly and securely. Any personal or health-related information collected through this website is used solely for the purpose of providing and improving our services, and it will not be shared with third parties without your consent, except as required by law. By using this site, you agree to our Privacy Policy, which outlines how we collect, use, and protect your information. For more details, please review our Privacy Policy and Terms of Use.”